A description of Canadian and United States physician reimbursement for thrombolytic therapy administration in acute ischemic stroke

Stroke

Volumn 36, Issue 3, 2005, Pages 682-687

  Kleindorfer, Dawn ^a   Hill, Michael D ^b   Woo, Daniel ^a   Tomsick, Thomas ^a   Pancioli, Arthur ^a   Kissela, Brett ^a   Demchuk, Andrew M ^b   Losiewicz, David ^c   Jauch, Edward ^a   Schneider, Alexander ^a   Ringer, Andrew ^a   Kanter, Daniel ^a   Broderick, Joseph P ^a  

^a UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF CALGARY   (Canada)

^c University Neurology Inc   (United States)

Author keywords

Stroke, acute; Stroke, ischemic; Thrombolytic therapy; Tissue plasminogen activator

Indexed keywords

ALTEPLASE;

ARTICLE; CANADA; CEREBROVASCULAR ACCIDENT; FIBRINOLYTIC THERAPY; HEALTH CARE PLANNING; HEALTH SURVEY; HOSPITAL BILLING; HUMAN; MAJOR CLINICAL STUDY; MEDICAL PRACTICE; PHYSICIAN INCOME; PRIORITY JOURNAL; REIMBURSEMENT; UNITED STATES;

ALBERTA; CANADA; CEREBROVASCULAR ACCIDENT; FEE-FOR-SERVICE PLANS; HUMANS; ISCHEMIC ATTACK, TRANSIENT; KENTUCKY; PHYSICIANS; THROMBOLYTIC THERAPY; UNITED STATES;

EID: 20044382047     PISSN: 00392499     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.STR.0000155742.46437.65     Document Type: Article

References (16)

1. Kleindorfer D, Kissela B, Woo D, Khoury J, Alwell K, Miller R, Gebel J, Szaflarski J, Pancioli A, Jauch E, Moomaw C, Shukla R, Broderick JP. The effect of race and gender on patterns of rt-PA use within a population. J Stroke Cerebravasc Dis. 2003;12:217-220.
2. Johnston SC, Fung LH, Gillum LA, Smith WS, Brass LM, Lichtman JH, Brown AN. Utilization of intravenous tissue-type plasminogen activator for ischemic stroke at academic medical centers: the influence of ethnicity. Stroke. 2001;32:1061-1068.
3. Morgenstern LB, Staub L, Chan W, Wein TH, Bartholomew LK, King M, Felberg RA, Burgin WS, Groff J, Hickenbottom SL, Saldin K, Demchuk AM, Kalra A, Dhingra A, Gratta JC. Improving delivery of acute stroke therapy: the TLL Temple Foundation stroke project. Stroke. 2002;33: 160-166.
4. Barber PA, Zhang J, Demchuk AM, Hill MD, Buchan AM. Why are stroke patients excluded from TPA therapy? An analysis of patient eligibility. Neurology. 2001;56:1015-1020.
5. Kleindorfer D, Kissela B, Schneider A, Woo D, Khoury J, Miller R, Alwell K, Gebel J, Szaflarski J, Pancioli A, Jauch E, Moomaw C, Shukla R, Broderick JP. Eligibility for recombinant tissue plasminogen activator in acute ischemic stroke: a population-based study. Stroke. 2004;35: e27-e29.
6. Pancioli AM, Broderick J, Kothari R, Brott T, Tuchfarber A, Miller R, Khoury J, Jauch E. Public perception of stroke warning signs and knowledge of potential risk factors. JAMA. 1998;279:1288-1292.
7. Schneider AT PA, Khoury JC, Rademacher E, Tuchfarber A, Miller R, Woo D, Kissela B, Broderick JP. Trends in community knowledge of the warning signs and risk factors for stroke. JAMA. 2003;289:343-346.
8. NINDS rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med. 1995;333:1581-1587.
9. Katzan IL, Graber TM, Furlan AJ, Sundararajan S, Sila CA, Houser G, Landis DM. Cuyahoga county operation stroke speed of emergency department evaluation and compliance with National Institutes of Neurological Disorders and Stroke time targets. Stroke. 2003;34:994-998.
10. Katzan IL, Sila CA, Furlan AJ. Community use of intravenous tissue plasminogen activator for acute stroke: Results of the brain matters stroke management survey. Stroke. 2001;32:861-865.
11. Kleindorfer D, Khoury J, Alwell K, Miller R, Shukla R, Kissela BM, Panagos P, Schneider A, Woo D, Moomaw CJ, Broderick J. Rtpa use in a population-based study: the post-PDA approval era. Stroke. 2003; 34:283.
12. American Medical Association. Current Procedural Terminology (CPT). Chicago, Ill: American Medical Association Press; 2004.
13. Hill MD, Barber PA, Demchuk AM, Sevick RJ, Newcommon NJ, Green T, Buchan AM. Building a "brain attack" team to administer thrombolytic therapy for acute ischemic stroke. Can Med Assoc J. 2000;162: 1589-1593.
14. Ernst R, Pancioli A, Tomsick T, Kissela B, Woo D, Kanter D, Jauch E, Carrozzella J, Spilker J, Broderick J. Combined intravenous and intra-arterial recombinant tissue plasminogen activator in acute ischemic stroke. Stroke. 2000;31:2552-2557.
15. Furlan A, Higashida R, Wechsler L, Gent M, Rowley H, Kase C, Pessin M, Ahuja A, Callahan F, Clark WM, Silver F, Rivera F. Intra-arterial prourokinase for acute ischemic stroke. The PROACT II study: a randomized controlled trial. Prolyse in Acute Cerebral Thromboembolism. JAMA. 1999;282:2003-2011.
16. Pagan SC, Morgenstern LB, Petitta A, Ward RE, Tilley BC, Marler JR, Levine SR, Broderick JP, Kwiatkowski TG, Frankel M, Brott TG, Walker MD. Cost-effectiveness of tissue plasminogen activator for acute ischemic stroke. NINDS rt-PA Stroke Study Group. Neurology. 1998;50: 883-890.